Mark V. Pauly, PhD

home / authors / mark-v-pauly-phd

Articles

January 15th 2005

Spillover Effects of Restrictive Drug Formularies: A Case Study of PacifiCare in California

Y. Richard Wang, MD, PhD Mark V. Pauly, PhD

October 1st 2003

Impact of Maine's Medicaid Drug Formulary Change on Non-Medicaid Markets: Spillover Effects of a Restrictive Drug Formulary

Y. Richard Wang, MD, PhD Mark V. Pauly, PhD Y. Aileen Lin, MS

April 1st 2003

Difference in the Use of Preventive Services Between Fee-for-Service Plans and HMOs: Is More Better?

Y. Richard Wang, MD, PhD Mark V. Pauly, PhD

Latest Updated Articles

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Blood smear AML | image credit: Chansom Pantip - stock.adobe.com

Published: October 20th 2024 | Updated: November 8th 2024

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions